CliffBio
small molecule

SOAANZ

TORSEMIDE

Loss of exclusivityOctober 2033latest FDA-listed patent expiry
CompanySarfez Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameSOAANZ
Active ingredientTORSEMIDE
Strength60MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2021
Marketing statusDISCN

Listed patents

PatentExpiresType
10154963October 2033product

More from Sarfez Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SOAANZ patent cliff — loss of exclusivity October 2033 | CliffBio